Hepatocyte growth factor overexpression promotes osteoclastogenesis and exacerbates bone loss in CIA mice

• Published in: Journal of orthopaedic translation 2021-03, Vol.27, p.9-16
• Main Authors: Huang, Chaoming, Zheng, Yufan, Bai, Jinyu, Shi, Ce, Shi, Xin, Shan, Huajian, Zhou, Xiaozhong
• Format: Article
• Language: English
• Subjects: HGF; Original; Osteoclast; Rheumatoid arthritis
• ISSN: 2214-031X; 2214-0328
• DOI: 10.1016/j.jot.2020.10.011

Hepatocyte growth factor (HGF) is a multifunctional growth factor that promotes various biological processes. However, the effect of HGF on bone metabolism in rheumatoid arthritis (RA) remains unknown. Here, we investigated the role of HGF in regulating osteoclastogenesis and bone resorption in RA. The expression of HGF in RA patients and collagen-induced arthritis (CIA) mice was examined. The role of HGF on osteoclastogenesis was analysed by osteoclastogenesis and bone resorption assays. The effect of HGF inhibition was evaluated in a CIA mice model. The mechanism of HGF in regulating osteoclastogenesis and bone resorption was explored by a series of in vitro studies. HGF was overexpressed in CIA and RA. HGF stimulated osteoclastogenesis in vitro. SU11274, a selective small molecule blocker of c-Met, impeded the effect of HGF on osteoclastogenesis and bone resorption. HGF regulated osteoclastogenesis by JNK and AKT-GSK-3β-NFATc1 signallings. SU11274 protected CIA mice from pathological bone loss. These data strongly suggest that the highly expressed HGF in the joint tissues contributes to bone loss in RA. Inhibition of HGF/c-Met could effectively alleviate pathological bone loss and inflammatory symptoms in CIA mice. HGF/c-Met may be used as a new target for the treatment of bone loss in RA.